The MammaPrint “70 gene detection” technique provides an important prognostic tool for ERPR-positive and HER2-negative patients with breast cancer, and the score is calculated at RNA transcriptional level [7–14]. This evidence concerns the gene ERBB2 and breast carcinoma.